Akoya Biosciences enables high-parameter, deep proteomic profiling of tissues.
Initial public offering in 2021 (NASDAQ:AKYA). Acquired by Quanterix in 2025.
Menu
Menu
Akoya Biosciences enables high-parameter, deep proteomic profiling of tissues.
Initial public offering in 2021 (NASDAQ:AKYA). Acquired by Quanterix in 2025.
300 Montgomery Street
Suite 1130
San Francisco, CA 94104
